Cargando…

(64)Cu-ATSM/(64)Cu-Cl(2) and their relationship to hypoxia in glioblastoma: a preclinical study

BACKGROUND: Diacetyl-bis(N4-methylthiosemicarbazone), labeled with 64Cu ((64)Cu-ATSM) has been suggested as a promising tracer for imaging hypoxia. However, various controversial studies highlighted potential pitfalls that may disable its use as a selective hypoxic marker. They also highlighted that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pérès, Elodie A., Toutain, Jérôme, Paty, Louis-Paul, Divoux, Didier, Ibazizène, Méziane, Guillouet, Stéphane, Barré, Louisa, Vidal, Aurélien, Cherel, Michel, Bourgeois, Mickaël, Bernaudin, Myriam, Valable, Samuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923301/ https://www.ncbi.nlm.nih.gov/pubmed/31858290 http://dx.doi.org/10.1186/s13550-019-0586-6

Ejemplares similares

Assessment of hypoxia and oxidative-related changes in a lung-derived brain metastasis model by [(64)Cu][Cu(ATSM)] PET and proteomic studies
por: Fantin, Jade, et al.
Publicado: (2023)

Focus on the Controversial Aspects of (64)Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging
por: Colombié, Mathilde, et al.
Publicado: (2015)

(64)Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry
por: Hansen, Anders E, et al.
Publicado: (2012)

Pharmacokinetic Analysis of (64)Cu-ATSM Dynamic PET in Human Xenograft Tumors in Mice
por: Li, Fan, et al.
Publicado: (2015)

Modification of intracellular glutathione status does not change the cardiac trapping of (64)Cu(ATSM)
por: Shaughnessy, Fiona, et al.
Publicado: (2014)

Tissue acidosis does not mediate the hypoxia selectivity of [(64)Cu][Cu(ATSM)] in the isolated perfused rat heart
por: Baark, Friedrich, et al.
Publicado: (2019)

Development of an automated production process of [(64)Cu][Cu (ATSM)] for positron emission tomography imaging and theranostic applications
por: Liu, Tengzhi, et al.
Publicado: (2022)

[(18)F]Fludarabine-PET as a promising tool for differentiating CNS lymphoma and glioblastoma: Comparative analysis with [(18)F]FDG in human xenograft models
por: Hovhannisyan, Narinée, et al.
Publicado: (2018)

Impact of [(64)Cu][Cu(ATSM)] PET/CT in the evaluation of hypoxia in a patient with Glioblastoma: a case report
por: Gangemi, Vincenzo, et al.
Publicado: (2019)

Validation of (64)Cu-ATSM damaging DNA via high-LET Auger electron emission
por: McMillan, Dayton D., et al.
Publicado: (2015)

(64)Cu-ATSM Predicts Efficacy of Carbon Ion Radiotherapy Associated with Cellular Antioxidant Capacity
por: Nachankar, Ankita, et al.
Publicado: (2021)

Pre-clinical Positron Emission Tomography Reconstruction Algorithm Effect on Cu-64 ATSM Lesion Hypoxia
por: Sanghera, Bal, et al.
Publicado: (2016)

Multimodal evaluation of hypoxia in brain metastases of lung cancer and interest of hypoxia image-guided radiotherapy
por: Corroyer-Dulmont, Aurélien, et al.
Publicado: (2021)

Hypoxia imaging and theranostic potential of [(64)Cu][Cu(ATSM)] and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms
por: Liu, Tengzhi, et al.
Publicado: (2020)

64Cu-ATSM Hypoxia Positron Emission Tomography for Detection of Conduit Ischemia in an Experimental Rat Esophagectomy Model
por: Park, Seong Yong, et al.
Publicado: (2015)

Cerebral Oxidative Stress in Early Alzheimer’s Disease Evaluated by (64)Cu-ATSM PET/MRI: A Preliminary Study
por: Okazawa, Hidehiko, et al.
Publicado: (2022)

Radionuclide Cisternography with [(64)Cu]Cu-DOTA
por: Greiser, Julia, et al.
Publicado: (2023)

(64)Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia in human colon carcinoma xenografts
por: Yoshii, Yukie, et al.
Publicado: (2017)

Multiple Administrations of (64)Cu-ATSM as a Novel Therapeutic Option for Glioblastoma: a Translational Study Using Mice with Xenografts
por: Yoshii, Yukie, et al.
Publicado: (2017)

Feasibility of Renal Blood Flow Measurement Using (64)Cu-ATSM PET/MRI: A Quantitative PET and MRI Study
por: Nishikawa, Yudai, et al.
Publicado: (2023)

Pilot Study of (64)CuCl(2) for PET Imaging of Inflammation
por: Jiang, Lei, et al.
Publicado: (2018)

Uniform intratumoral distribution of radioactivity produced using two different radioagents, (64)Cu-cyclam-RAFT-c(-RGDfK-)(4) and (64)Cu-ATSM, improves therapeutic efficacy in a small animal tumor model
por: Jin, Zhao-Hui, et al.
Publicado: (2018)

Evaluation of hypoxia in a feline model of head and neck cancer using (64)Cu-ATSM positron emission tomography/computed tomography
por: Ballegeer, Elizabeth A, et al.
Publicado: (2013)

ET-7 EVALUATION OF HYPOXIA-TARGETING RADIOPHARMACEUTICAL(64)CU-ATSM FOR PET MONITORING WITH LOCAL THERAPY IN HIGH-GRADE GLIOMA MODEL
por: Yoshii, Yukie, et al.
Publicado: (2022)

Comparison of the Effects of DOTA and NOTA Chelators on (64)Cu-Cudotadipep and (64)Cu-Cunotadipep for Prostate Cancer
por: Lee, Inki, et al.
Publicado: (2023)

Cu(II)(atsm) Attenuates Neuroinflammation
por: Choo, Xin Yi, et al.
Publicado: (2018)

Comparison of Immuno-PET of CD138 and PET imaging with (64)CuCl(2) and (18)F-FDG in a preclinical syngeneic model of multiple myeloma
por: Bailly, Clément, et al.
Publicado: (2018)

Recent Advances in (64)Cu/(67)Cu-Based Radiopharmaceuticals
por: Krasnovskaya, Olga O., et al.
Publicado: (2023)

In vivo [(64)Cu]CuCl(2) PET imaging reveals activity of Dextran-Catechin on tumor copper homeostasis
por: Parmar, Arvind, et al.
Publicado: (2018)

Controlled Administration of Penicillamine Reduces Radiation Exposure in Critical Organs during (64)Cu-ATSM Internal Radiotherapy: A Novel Strategy for Liver Protection
por: Yoshii, Yukie, et al.
Publicado: (2014)

Micro Regional Heterogeneity of (64)Cu-ATSM and (18)F-FDG Uptake in Canine Soft Tissue Sarcomas: Relation to Cell Proliferation, Hypoxia and Glycolysis
por: Zornhagen, Kamilla Westarp, et al.
Publicado: (2015)

(64)Cu-based Radiopharmaceuticals in Molecular Imaging
por: Zhou, Yeye, et al.
Publicado: (2019)

Radiobiological Characterization of (64)CuCl(2) as a Simple Tool for Prostate Cancer Theranostics
por: Guerreiro, Joana Fernandes, et al.
Publicado: (2018)

A Prospective Study Assessing the Post-Prostatectomy Detection Rate of a Presumed Local Failure at mpMR with Either (64)CuCl(2) or (64)CuPSMA PET/CT
por: Faiella, Adriana, et al.
Publicado: (2021)

Synthesis and evaluation of (64)Cu-radiolabeled NOTA-cetuximab ((64)Cu-NOTA-C225) for immuno-PET imaging of EGFR expression
por: Xu, Xiaoxia, et al.
Publicado: (2019)

Harnessing (64)Cu/(67)Cu for a theranostic approach to pretargeted radioimmunotherapy
por: Keinänen, Outi, et al.
Publicado: (2020)

Theragnostic (64)Cu/(67)Cu Radioisotopes Production With RFT-30 Cyclotron
por: Lee, Jun Young, et al.
Publicado: (2022)

[(64)Cu]Cu-DOTATATE PET metrics in the investigation of atherosclerotic inflammation in humans
por: Jensen, Jacob K., et al.
Publicado: (2022)

The somatostatin receptor 2 antagonist (64)Cu-NODAGA-JR11 outperforms (64)Cu-DOTA-TATE in a mouse xenograft model
por: Rylova, Svetlana N., et al.
Publicado: (2018)

Biokinetic and dosimetric aspects of (64)CuCl(2) in human prostate cancer: possible theranostic implications
por: Righi, Sergio, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_slljhkk9df41fvvo5bdn5hfhac